Literature DB >> 21876256

Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.

Jens Peter Reese1, Philipp Hessmann, Greta Seeberg, Dajana Henkel, Pamela Hirzmann, Jürgen Rieke, Erika Baum, Frank Dannhoff, Matthias J Müller, Frank Jessen, Monika-Balzer Geldsetzer, Richard Dodel.   

Abstract

The study aims to report service use and costs for patients with Alzheimer's disease (AD) and to explore the incremental influence of sociodemographic and illness-related determinants in ambulatory and inpatient settings within the German health care system. 395 patients with dementia were recruited at the following sites: 1) University hospital, 2) general practitioners' offices, 3) office-based neurologists, 4) a regional psychiatric hospital, and 5) nursing homes. Sociodemographic, economic, and clinical parameters were assessed using a standardized questionnaire. Informal care was not evaluated. Disease severity was measured using the Mini-Mental Status Examination and the Alzheimer's Disease Assessment Scale - Cognitive Subscale. Neuropsychiatric status was assessed using the Geriatric Depression Scale, the Neuropsychiatric Inventory, and the Alzheimer's Disease Cooperative-Study-Activities of Daily Living. Annual total costs were estimated to be €13,080 per patient. The most important cost component was (long-term) care, constituting about 43% of total costs. Indirect costs comprised about 18% of total costs and were mainly due to reductions in working time of caregivers. Poorer functional status was associated with higher total and caregiving costs. In multivariate analyses, we identified younger age, female gender, and impaired activities of daily living as independent predictors of higher costs. Given that care for patients with AD is complex and expensive, our models were only able to explain about 17-43% of the variability in total costs. This suggests that further social and individual factors considerably influence the costs associated with AD. Direct medical care costs and long-term care costs related differently to the patient's clinical characteristics. Longitudinal and population-based studies are necessary for thoroughly evaluating the burden of disease.

Entities:  

Mesh:

Year:  2011        PMID: 21876256     DOI: 10.3233/JAD-2011-110539

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

Review 1.  Measuring the impact of informal elderly caregiving: a systematic review of tools.

Authors:  Isabel Mosquera; Itziar Vergara; Isabel Larrañaga; Mónica Machón; María del Río; Carlos Calderón
Journal:  Qual Life Res       Date:  2015-10-16       Impact factor: 4.147

2.  Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.

Authors:  Geke A H van den Elsen; Amir I A Ahmed; Robbert-Jan Verkes; Cees Kramers; Ton Feuth; Paul B Rosenberg; Marjolein A van der Marck; Marcel G M Olde Rikkert
Journal:  Neurology       Date:  2015-05-13       Impact factor: 9.910

3.  Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.

Authors:  J Darbà; L Kaskens; L Lacey
Journal:  Eur J Health Econ       Date:  2014-10-28

4.  Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial.

Authors:  Bernhard Michalowsky; Steffen Flessa; Tilly Eichler; Johannes Hertel; Adina Dreier; Ina Zwingmann; Diana Wucherer; Henriette Rau; Jochen René Thyrian; Wolfgang Hoffmann
Journal:  Eur J Health Econ       Date:  2017-02-03

5.  Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study.

Authors:  Erik Meijer; Maria Casanova; Hyewon Kim; Ana Llena-Nozal; Jinkook Lee
Journal:  Lancet Reg Health Eur       Date:  2022-06-24

6.  Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.

Authors:  Susanne Hartz; Denis Getsios; Sunning Tao; Steve Blume; Grant Maclaine
Journal:  BMC Neurol       Date:  2012-02-08       Impact factor: 2.474

7.  Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer's disease.

Authors:  Maria Biasutti; Natacha Dufour; Clotilde Ferroud; William Dab; Laura Temime
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

8.  Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer's disease.

Authors:  Joosep Kalamägi; Piia Lavikainen; Heidi Taipale; Antti Tanskanen; Jari Tiihonen; Sirpa Hartikainen; Anna-Maija Tolppanen
Journal:  Ann Med       Date:  2019-08-12       Impact factor: 5.348

9.  Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain.

Authors:  Josep Darbà; Lisette Kaskens
Journal:  Clinicoecon Outcomes Res       Date:  2015-07-02

10.  Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data.

Authors:  Larissa Schwarzkopf; Petra Menn; Reiner Leidl; Elmar Graessel; Rolf Holle
Journal:  BMC Health Serv Res       Date:  2013-01-03       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.